|
Needle Safety Devices Market Insights, Competitive Landscape, and Market Forecast – 2034” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. As per DelveInsight’s assessment, The expansion of the needle safety devices … Continue reading
|
Hodgkin’s Lymphoma – Pipeline Insight, 2026 DelveInsight’s “Hodgkin’s Lymphoma – Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies, including Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others, … Continue reading
|
|
Novartis’s COSENTYX (Secukinumab) Approved by the FDA for Pediatric Hidradenitis Suppurativa DelveInsight Analysis: What Novartis’s COSENTYX (Secukinumab) Approval by the FDA for Pediatric Hidradenitis Suppurativa Means for the Hidradenitis Suppurativa Treatment Market, Biologic Competition, and Commercial Strategy? On March 13, … Continue reading
|
Mammography devices market The global mammography devices market is set for strong, sustained expansion, driven by companies such as, SternMed GmbH, FUJIFILM Corporation, Hologic Inc., Planmed OY, General Electric Company (GE Healthcare), Siemens Healthcare GmbH, Koninklijke Philips NV, DMS Group, … Continue reading
|
|
Fetal monitoring devices market Insights The global fetal monitoring devices market is set for strong, sustained expansion, driven by companies such as General Electric Company (GE Healthcare), Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Cardinal Health, Inc., Siemens Healthcare GmbH, Natus … Continue reading
|
DelveInsight’s, “Cutaneous Lupus Erythematosus Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the Cutaneous Lupus Erythematosus Pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading
|
|
DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical … Continue reading
|
DelveInsight’s “Acute Myeloid Leukemia Pipeline Insights 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and … Continue reading
|
|
DelveInsight’s, “HDAC Inhibitor Pipeline Insights 2026” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HDAC Inhibitor pipeline landscape. It covers the HDAC Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading
|
DelveInsight’s, “Follicular Lymphoma Pipeline Insight, 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading
|
